As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.
As the manufacturer of Advantage™ I-125 and Pd-103 seeds for over 20 years, IsoAid specializes in providing Brachytherapy seeds for the treatment of prostate, ocular and breast cancer, as well as for diagnostic localization purposes. We are a full-service company you can always rely on, making seeds at the activity you request, custom-loading and delivering them faster than anyone in the industry. Through our exclusive partnership with Eye Physics we give you access to cutting edge eye plaques and planning services, which deliver many clinical advantages to you and your patients. High-activity seeds are custom-loaded using COMS or Eye Physics plaques. Our innovate Secure Strand™ cuts down significantly on seed migration for prostate patients and is now being used for RSL with great success. Our team of experts is dedicated to helping with every aspect of your program and is happy to serve as a complete resource for you. IsoAid is invested in the future of Brachytherapy and we look forward to introducing you to some exciting new advances very soon.
Theragenics partners with physicians, healthcare providers, and medical associations to deliver effective cancer treatments to patients worldwide. Our brachytherapy portfolio includes the industry leading TheraSeed® Palladium-103 seed and AgX100® Iodine-125 seed, both sourced and manufactured within North America.
As a brachytherapy pioneer, Theragenics is known for delivering quality seeds, strands, pre-loaded needles, and carriers, all with personalized service. And because we’re committed to providing effective, minimally invasive treatment options with minimal side effects, we continue to invest in this space. For more information, please visit www.theragenics.com.
At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. We develop and deliver innovative cancer care technologies to support every step of the journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while pursuing clinical research to create a more efficient, personalized care pathway for millions of patients each year. To learn more about our solutions, go to http://www.varian.com.
Best Medical International (BMI), a TeamBest Global company, encompasses a family of trusted organizations and companies that specialize in providing innovative, high-quality, and efficient solutions for brachytherapy, vascular brachytherapy, and external beam radiation therapy. BMI manufactures and supplies Iodine-125 and Palladium-103 seeds, needles, templates, applicators, catheters, fiducial markers, dosimeter systems, the NovosteTM Beta-CathTM System, and a variety of other products for brachytherapy and other radiation therapy applications. Additionally, BMI and other TeamBest companies manufacture a wide range of products such as cyclotrons for medical isotopes production, GammaBeam teletherapy systems, blood irradiators, particle therapy accelerators, AccuBoost system, QA/QC instruments and ultrasound imaging systems. Our goal is to become the go-to partner for clinicians who seek all their radiation therapy and oncology product and service requirements.
Empowering the evolution of care for patients with cancer.
Blue Earth Diagnostics is an established molecular imaging company on a growth trajectory to provide innovative, well differentiated diagnostics solutions, informing patients and driving future therapies in cancer. Formed in 2014, Blue Earth Diagnostics' success is driven by our management expertise and agility, supported by our demonstrated track record of rapid development and commercialization of PET radiopharmaceuticals. Blue Earth Diagnostics’ clinical focus is exclusively in cancer.
